Frequently Asked Questions

The specific injury models the research examined, what a rodent model can and cannot establish, and how a tendon study in rats became “the healing peptide”.

Which indications have reported and which are still running — organised by how far the evidence has actually travelled, not by what the compound might do.

Which indication sits on which brand's label, what the trials behind them measured, and why a research-market vial carries no indication at all.

The three approved indications, the programme behind each, and what the GIP arm does and does not explain about the results.

There is no single correct volume — the water sets the concentration, and the concentration sets the syringe units. The reference table converts vial size and volume into units for the trial dose points.

The volume-to-concentration-to-units arithmetic for the 5 mg and 10 mg vials, tabulated against the labelled dose ladder.

The volume-to-concentration-to-units arithmetic for the 10, 30 and 60 mg vials, tabulated against the labelled ladder — including where a vial cannot hold a dose at all.

Why no trial-established dose exists, where the 250 and 500 mcg figures actually came from, and what the species extrapolation behind them assumes.

The doses the retatrutide trials actually administered — Phase 2's 0.5-12 mg range and the Phase 3 TRIUMPH escalation — and why no approved dosing standard exists.

Why there is no such thing as “the semaglutide dose” — four labels, four ceilings and four different missed-dose rules, each attributed to the label it comes from.

The labelled escalation ladder and its ceiling, why the steps are four weeks apart, and the missed-dose rule as the labels actually write it.

Why there is no established BPC-157 dosing frequency — the circulating numbers are convention, and the cited evidence is animal-model plus one small human case series.

Why the pair's frequency splits by half-life — CJC-1295 DAC weekly vs no-DAC CJC and Ipamorelin multiple times daily — with the combination's no-trial caveat.

The once-weekly subcutaneous schedule and every-4-week titration the retatrutide trials used, reported from the profile's cited Phase 2/3 protocols.

The once-weekly injectable schedule (0.25→2.4 mg), the Ozempic/Rybelsus variants, and the every-4-week titration the semaglutide trials and label used.

Why there is no established TB-500 dosing frequency — the loading/maintenance numbers are convention, and the cited studies are mechanism/wound-healing with an animal-estimated half-life.

The once-weekly subcutaneous schedule and every-4-week titration (2.5→15 mg) the tirzepatide trials and FDA label used.

Why there is no characterised human side-effect profile, what “no toxic dose identified” does and does not mean, and the angiogenesis question the literature leaves open.

The one cited IGF-1 LR3 side effect (hypoglycemia) versus what is not established — the analog has no controlled human trials, and the cited sources leave the IGF-1/cancer question open.

Why there is no blend-level side-effect data for KLOW — no trial has studied the four-peptide combination, so side effects are per-component, and each component's human safety data is limited or absent.

The reported rates with the trial behind each, the dysesthesia finding that is specific to retatrutide, and what trial safety data does not tell you about a research-market vial.

The reported rates with the trial behind each, why escalation is when they cluster, and what a label warns about that a trial did not measure.

Why there is no characterized human side-effect profile for thymosin beta-4 / TB-500 — human exposure is two terminated Phase 2 trials, the cited studies are animal wound-healing mechanism, and the tumor question stays theoretical.

The reported rates with the trial behind each, the head-to-head discontinuation figure, and what a boxed warning drawn from rodent data does and does not establish.